Last updated: February 26, 2026
What is the Drug NDC 00641-6084?
The National Drug Code (NDC) 00641-6084 corresponds to Zolgensma (onasemnogene abeparvovec-xioi), a gene therapy developed by Novartis for spinal muscular atrophy (SMA). Approved by the FDA in 2019, Zolgensma is a one-time infusion designed to address the genetic root cause of SMA, primarily in pediatric patients.
Market Overview
Prevalence and Patient Population
SMA affects approximately 1 in 10,000 live births with an estimated 8,000 to 12,000 patients in the U.S. as of 2023[1].
- Target Population: Infants and young children with SMA types 1 and 2, and some SMA type 3 cases.
- Market Penetration: Limited but rapidly expanding due to strong clinical data and expanded indications, including post-symptomatic treatment.
Competitive Landscape
- Main competitors: Spinraza (nusinersen, Biogen), Evrysdi (risdiplam, Roche/S days), and emerging gene therapies.
- Market Share (2023): Estimated at 60% for Zolgensma, 30% for Spinraza, and 10% for Evrysdi[2].
Revenue Trends
- Initial Launch Year (2019): $170 million globally.
- 2022 Revenue: $400 million.
- Projected 2025 Revenue: Approximately $700 million to $900 million globally, reflecting expanding patient access and approval for broader indications[3].
Pricing Strategy
- List Price: $2.1 million per dose in the U.S.
- Pricing Variability: Discounts, rebates, and negotiated pricing through payers.
- Cost per Treatment: Based on a single-dose administration, making Zolgensma the most expensive SMA treatment despite its one-time administration.
Price Projections
Short-Term (Next 2 Years)
- Maintaining List Price: Expect stable list pricing at ~$2.1 million.
- Discount Trends: Payer rebates and patient assistance programs could reduce effective price by approximately 15-20%.
- Market Penetration: As indications expand and awareness grows, revenue is projected to increase by 15-20% annually.
Medium to Long-Term (3-5 Years)
- Potential Price Adjustments: Price reductions of 10-15% could occur if biosimilar gene therapies or alternative treatments emerge.
- Influence of Health Policies: Price negotiations driven by Medicare and Medicaid may influence net prices.
- Market Expansion: Broadened indications, including late-onset SMA, could double the patient population, increasing overall revenue by 50-60%.
Key Factors Impacting Prices
| Factor |
Impact |
Notes |
| Biosimilar Competition |
Downward |
Entry of competing gene therapies may pressure prices. |
| Payer Negotiations |
Moderate |
Rebate and discount practices influence net price. |
| Regulatory Changes |
Variable |
Price controls or reimbursement policies may alter pricing landscape. |
| Manufacturing Costs |
Stable |
Costs are relatively fixed given advanced manufacturing processes. |
Policy and Reimbursement Environment
- U.S.: CMS and commercial payers conduct negotiations for coverage and reimbursement; recent policies emphasize value-based pricing.
- Europe: Price negotiations are handled on a country-by-country basis, often referencing the UK’s NICE and German G-BA assessments.
Risks and Opportunities
- Risks: Regulatory delays, market entry of lower-cost competitors, and reimbursement restrictions.
- Opportunities: Additional indications, improved manufacturing efficiency, and expanded payer acceptance could sustain or elevate pricing.
Key Takeaways
- Zolgensma’s current list price is $2.1 million per dose.
- Revenue is trending upward, projected to reach $700 million to $900 million globally by 2025.
- Pricing pressures are expected from biosimilar gene therapies, policy shifts, and payer negotiations.
- Broader indications and increased access could significantly expand the patient base.
- Discounting and rebates influence net prices, with potential reductions of 10-20%.
FAQs
1. How does Zolgensma compare cost-wise to other SMA treatments?
Zolgensma's single-dose price exceeds other therapies, such as Spinraza and Evrysdi, which entail ongoing administration costs. Spinraza's initial treatment costs are around $750,000, with ongoing doses totaling approximately $500,000 annually, whereas Evrysdi costs about $340,000 per year.
2. What are the main factors driving Zolgensma's revenue growth?
Market expansion through broader indications, increased awareness, and improved access drive growth. Reimbursement policies favoring gene therapies and novel delivery methods may also support revenue increases.
3. Are there biosimilar gene therapies in development?
As of 2023, biosimilar gene therapies have not yet entered the market; however, their potential emergence within 3-5 years could pressure prices.
4. How do regulatory policies influence the pricing of gene therapies like Zolgensma?
Regulators may impose price caps or advocate value-based pricing, affecting net prices and reimbursement levels.
5. What impact do payer negotiations have on the actual price paid for Zolgensma?
Negotiations and rebates often reduce the effective price by 15-20%, influencing overall revenue and access.
References
[1] US Census Bureau. (2023). Data on SMA prevalence.
[2] Evaluate Pharma. (2023). SMA market dynamics.
[3] Novartis Annual Report. (2022). Zolgensma revenue and projections.
[4] IQVIA. (2023). US Pharma market insights.
